Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C] - Larotinib in Healthy Male Participants
Latest Information Update: 23 Mar 2023
At a glance
- Drugs Larotinib (Primary)
- Indications Oesophageal cancer
- Focus Pharmacokinetics
- Sponsors Sunshine Lake Pharma
- 20 Mar 2023 Status changed from active, no longer recruiting to completed.
- 09 Mar 2022 Status changed from not yet recruiting to active, no longer recruiting.
- 30 Sep 2021 New trial record